In reply, it would just point out PPHM's entire communications MO is overwhelmingly cautious and conservative. I don't think they would re-brand the Company and announce both preclinical immunotherapy combo studies AND a clinical immunotherapy combo study to start before year-end unless the "well advanced" preclinical work had already yielded some very encouraging data.